Market Cap | 303.01M | P/E | - | EPS this Y | -1,553.30% | Ern Qtrly Grth | - |
Income | -9.06M | Forward P/E | -2.14 | EPS next Y | 27.40% | 50D Avg Chg | -6.00% |
Sales | 58.75M | PEG | 0.02 | EPS past 5Y | - | 200D Avg Chg | -17.00% |
Dividend | N/A | Price/Book | 2.77 | EPS next 5Y | -283.60% | 52W High Chg | -38.00% |
Recommedations | 1.70 | Quick Ratio | 4.28 | Shares Outstanding | 62.56M | 52W Low Chg | 67.00% |
Insider Own | 2.61% | ROA | -36.33% | Shares Float | 52.17M | Beta | 2.11 |
Inst Own | 100.65% | ROE | -6.15% | Shares Shorted/Prior | 8.60M/5.60M | Price | 4.90 |
Gross Margin | -197.55% | Profit Margin | -15.42% | Avg. Volume | 504,966 | Target Price | 24.80 |
Oper. Margin | -460.39% | Earnings Date | May 7 | Volume | 1,298,494 | Change | 0.41% |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
TD Cowen | Buy | Apr 9, 24 |
JMP Securities | Market Outperform | Apr 4, 24 |
Citigroup | Buy | Mar 11, 24 |
JMP Securities | Outperform | Mar 11, 24 |
HC Wainwright & Co. | Neutral | Mar 11, 24 |
BMO Capital | Outperform | Mar 8, 24 |
Stifel | Buy | Mar 8, 24 |
Barclays | Overweight | Mar 8, 24 |
BTIG | Buy | Mar 4, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Bonvini Ezio | Sr VP, Research & CS.. Sr VP, Research & CSO | Jan 19 | Sell | 12 | 13,316 | 159,792 | 87,984 | 01/22/24 |
BIOTECH TARGET N V | 10% Owner 10% Owner | Feb 14 | Buy | 5.0652 | 500,000 | 2,532,600 | 9,579,963 | 02/16/23 |
BIOTECH TARGET N V | 10% Owner 10% Owner | Dec 23 | Buy | 5.75 | 400,000 | 2,300,000 | 8,929,963 | 12/28/22 |
Koenig Scott | President and CEO President and CEO | May 16 | Option | 1.51 | 53,265 | 80,430 | 1,049,636 | 05/17/22 |
Karrels James | SVP, CFO and Secreta.. SVP, CFO and Secretary | Mar 28 | Option | 1.51 | 8,316 | 12,557 | 151,776 | 03/28/22 |
Risser Eric Blasius | Chief Operating Offi.. Chief Operating Officer | Mar 04 | Option | 0.94 | 500 | 470 | 44,968 | 03/04/22 |
BIOTECH TARGET N V | 10% Owner 10% Owner | Sep 20 | Buy | 20.44 | 600,000 | 12,264,000 | 6,875,564 | 09/20/21 |
Peters Jeffrey Stuart | General Counsel General Counsel | Mar 09 | Option | 11.5 | 21,749 | 250,114 | 21,749 | 03/09/21 |
Peters Jeffrey Stuart | General Counsel General Counsel | Mar 09 | Sell | 26.5 | 21,749 | 576,348 | 03/09/21 | |
Risser Eric Blasius | Sr VP & Chief Busine.. Sr VP & Chief Business Officer | Dec 01 | Option | 1.51 | 500 | 755 | 44,968 | 12/01/20 |
Risser Eric Blasius | Sr VP & Chief Busine.. Sr VP & Chief Business Officer | Dec 01 | Sell | 23.35 | 500 | 11,675 | 44,468 | 12/01/20 |
Risser Eric Blasius | Sr VP & Chief Busine.. Sr VP & Chief Business Officer | Oct 29 | Option | 1.51 | 1,500 | 2,265 | 45,968 | 10/29/20 |
Risser Eric Blasius | Sr VP & Chief Busine.. Sr VP & Chief Business Officer | Oct 29 | Sell | 20.69 | 1,500 | 31,035 | 44,468 | 10/29/20 |
Bonvini Ezio | Sr VP, Research & CS.. Sr VP, Research & CSO | Sep 21 | Sell | 30.94 | 62,851 | 1,944,610 | 83,807 | 09/21/20 |